Cubist Systematic Strategies’s Immuneering IMRX Stock Holding History

Cubist Systematic Strategies’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-29,404	Closed	-$99.1K	–	3250
2025 Q2	$99.1K	Buy	+29,404	New	+$50.4K	﹤0.01%	2712
2025 Q1	–	Sell	-659	Closed	-$1.45K	–	3142
2024 Q4	$1.45K	Sell	659 -1	-0.2%	-$2	﹤0.01%	2897
2024 Q3	$1.64K	Sell	660 -5,190	-89%	-$7.55K	﹤0.01%	2889
2024 Q2	$7.49K	Buy	+5,850	New	+$9.62K	﹤0.01%	2809
2022 Q3	–	Sell	-16,893	Closed	-$91K	–	4565
2022 Q2	$91K	Sell	16,893 -12,267	-42%	-$65.4K	﹤0.01%	4001
2022 Q1	$189K	Buy	+29,160	New	+$280K	﹤0.01%	3069

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cubist Systematic Strategies's IMRX Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Immuneering (IMRX) in Q3 2025, closing a stake of 29,404 shares — an estimated $99.1K sold.

Cubist Systematic Strategies first reported a position in IMRX in Q1 2022 and held it in 6 quarters. The position peaked at $189K in Q1 2022. 68 funds tracked by Wall St. Rank hold IMRX as of Q3 2025.

Cubist Systematic Strategies reported no remaining Immuneering position as of Q3 2025 after selling out during the quarter.
Cubist Systematic Strategies sold 29,404 Immuneering shares in Q3 2025, an estimated $99.1K.
Cubist Systematic Strategies first reported a position in Immuneering in Q1 2022 and held it in 6 quarters.
Cubist Systematic Strategies's Immuneering position peaked at $189K in Q1 2022.
68 funds tracked by Wall St. Rank held Immuneering as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.